Biogen Inc.
BIIBNASDAQ
Product information
What is Biogen Inc. (BIIB)?
Biogen is a US biotechnology company headquartered in Cambridge, Massachusetts. Its shares trade on Nasdaq under the ticker BIIB, and the company is included in the S&P 500 index. It was founded in 1978 by a group of scientists that included Nobel laureates, and it focuses on diseases of the nervous system.
The company's products are aimed mainly at multiple sclerosis, spinal muscular atrophy, Alzheimer's disease and rare neurological conditions. Tecfidera, Vumerity, Tysabri and Avonex are used in multiple sclerosis treatment and Spinraza in spinal muscular atrophy, while Leqembi is an Alzheimer's medicine developed together with Eisai. With the acquisition of Reata in 2023, Skyclarys, a medicine for Friedreich's ataxia, also joined the portfolio.
Those following Biogen stock typically watch generic competition for multiple sclerosis medicines, the pace at which the Alzheimer's medicine is adopted, clinical trial results and drug approval decisions. On the BIIB page at Lzzo.com, the share price is shown in US dollars, and the page includes a historical price chart and technical indicators.
Sources: biogen.com, investors.biogen.com
- Name
- Biogen Inc.
- Symbol
- BIIB
- Market
- Stocks
What to look for in the technical analysis of Biogen Inc.
Moving averages help assess the trend and RSI helps assess momentum. Indicators are calculated from real history; when there is not enough history or the required candle fields are missing, the indicator is not calculated. Past results do not guarantee future performance.
Technical indicators
Calculated from observed daily candles (at least 201 observations). No intraday indicators. Indicators are descriptive, not a buy/sell recommendation.
Investment Return CalculatorWith observed closes over the past year
Loading historical prices…